<DOC>
	<DOCNO>NCT01737697</DOCNO>
	<brief_summary>Acute Phase : It hypothesize ZS ( zirconium silicate ) effective placebo control ( alternative hypothesis ) lower S-K level subject S-K 5.0 - 6.5 mmol/l versus difference ZS placebo control ( null hypothesis ) . Subacute Phase ( randomize withdrawal ) : It hypothesize ZS daily effective placebo control ( alternative hypothesis ) maintain normokalemic level ( 3.5 - 4.9 mmol/l ) among subject complete Acute Phase versus difference ZS dose respective placebo control ( null hypothesis ) .</brief_summary>
	<brief_title>Safety &amp; Efficacy Zirconium Silicate Mild Moderate Hyperkalemia</brief_title>
	<detailed_description>A total 750 subject mild moderate hyperkalemia ( i- STAT potassium level 5.0-6.5 mmol/l , inclusive ) enrol study , double-blind fashion , randomize 1:1:1:1:1 receive one four ( 4 ) dos ZS ( 1.25g , 2.5g , 5g , 10g ) placebo control , administer 3 time daily ( tid ) meals initial 48 hour ( Acute Phase ) , follow Subacute Phase ( randomize withdrawal ) patient treat active dos Acute Phase , achieve normokalemia ( i-STAT potassium value 3.5 4.9 mmol/l , inclusive ) randomize 12 day subacute , day ( qd ) dosing . There one-time randomization assign Acute Phase treatment Subacute Phase treatment . The Subacute Phase include subject become normokalemic active drug become normokalemic placebo . The former randomize 1:1 ratio dose ZS receive acute phase administer day ( qd ) placebo , qd . Subjects placebo Acute Phase normokalemic morning Study Day 3 , randomize receive either 1.25 2.5 g ZS , qd Subacute Phase treatment . Safety tolerability assess ongoing basis Independent Data Safety Monitoring Board ( DSMB ) . Each active dose group consist 150 patient per treatment group include placebo control group total 750 patient ; 1:1:1:1:1 allocation help optimize multiple active dose comparison respective placebo control Subacute Phase .</detailed_description>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>Provision write informed consent . Over 18 year age . Mean iSTAT potassium value 5.0 6.5 mmol/l inclusive , screen ( Study Day 0 ) . Ability repeat blood draw effective venous catheterization . Women childbearing potential must practice highly effective method birth control . Pseudohyperkalemia sign symptom , excessive fist clinch hemolyzed blood specimen , severe leukocytosis thrombocytosis . Subjects treat lactulose , xifaxan nonabsorbed antibiotic hyperammonemia within last 7 day . Subjects treat resin ( Sevelamer acetate Sodium polystyrene sulfonate [ SPS ; e.g . KayexalateÂ® ] ) , calcium acetate , calcium carbonate , lanthanum carbonate , within last 7 day . Subjects life expectancy le 3 month . Subjects HIV positive . Subjects severely physically mentally incapacitated opinion investigator unable perform subject ' task associate protocol . Women pregnant , lactating , plan become pregnant . Subjects Ketoacidosis/Acidemia . Presence condition , opinion investigator , place subject undue risk potentially jeopardize quality data generate . Known hypersensitivity previous anaphylaxis ZS component thereof . Previous treatment ZS Treatment drug device within last 30 day receive regulatory approval time study entry . Subjects cardiac arrhythmia require immediate treatment . Insulindependent diabetes mellitus Subjects dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>